Diabetes drug may shield heart nerves from damage

NCT ID NCT07558863

Recruiting now Disease control Sponsor: The First Affiliated Hospital with Nanjing Medical University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether GLP-1 receptor agonists, a class of diabetes medications including semaglutide, can improve heart nerve damage in people with type 2 diabetes. 60 adults will receive either standard care or standard care plus a weekly injection for 6 months. Researchers will measure heart rate variability and other heart function tests to see if the drug helps protect the heart's nerves.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: GLP-1 receptor agonists (semaglutide or polyethylene glycol loxenatide)
What this could lead to: If it works, this could show that GLP-1 drugs protect against or improve diabetic heart nerve damage, reducing risks of heart attack and sudden death.
What could go wrong: This is a small, early-phase study with only 60 participants. Results may not apply to everyone, and the treatment may not improve nerve function beyond standard care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETES WITH DIABETIC AUTONOMIC NEUROPATHY (DIAGNOSIS) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diabetic autonomic neuropathy disease type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIABETES WITH DIABETIC AUTONOMIC NEUROPATHY (DIAGNOSIS) TYPE 2 DIABETES

Contacts and locations

Locations

the First Affiliated Hospital of Nanjing Medical University
RECRUITING

Nanjing, Jiangsu, 210029, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.